3 Libro 64
4.3 Poster 164
MitraClip Treatment for Severe Mitral Regurgitation Due to Chordae Rupture Following Impella CP Support in a Patient With Severe Aortic Stenosis
We report the case of an 85-year-old man with severe aortic stenosis who underwent high-risk percutaneous coronary intervention with Impella CP support. Unfortunately, the device caused mitral chordae tendineae rupture leading to severe mitral regurgitation. The patient underwent a staged fully percutaneous treatment with transcatheter aortic valve replacement followed by elective Mitraclip therapy. Echocardiographic monitoring is of paramount importance during Impella insertion and removal i...
Dual antiplatelet therapy duration after percutaneous coronary intervention with drug-eluting stents: how short can we go?
Current guidelines recommend a duration of dual antiplatelet therapy (DAPT) with aspirin and oral P2Y12 receptor inhibitors following percutaneous coronary intervention (PCI) with second-generation drug-eluting stents (DES) of 6 months for most patients with stable coronary disease and of 12 months for most patients with acute coronary syndromes. Large evidence from randomised clinical trials of shorter DAPT regimens after PCI with newer-generation DES is now emerging in heterogenous patient ...
Acute mitral regurgitation is a life-threatening pathology. Nowadays, percutaneous mitral valve repair with the MitraClip device offers, in selected patients, a safe and effective therapeutic alternative to open surgery. Hereby, we report the case of an 82-year-old woman with lateral ST-elevation myocardial infarction determining severe acute mitral regurgitation, who was treated with an urgent MitraClip procedure. Moreover, we discuss echocardiographic assessment of acute mitral regurgitatio...
The Placebo Effect on Symptoms, Quality of Life, and Functional Outcomes in Patients With Angina Pectoris: A Meta-analysis of Randomized Placebo-Controlled Trials
The placebo effect is a well described phenomenon in blinded studies evaluating antianginal therapeutics, although its effect on clinical research metrics remains unknown. We conducted a systematic review and meta-analysis to quantify the effect of placebo on end points of symptoms, life quality, and functional outcomes in randomized placebo-controlled trials (RCTs) of symptomatic stable coronary artery disease.
- 1 Contributo su Rivista16721
- 4 Contributo in Atti di Convegno ...1405
- 2 Contributo in Volume795
- 3 Libro64
- 6 Brevetti33
- 5 Altro24
Data di pubblicazione
- In corso di stampa20
- 2020 - 20222204
- 2010 - 20199885
- 2000 - 20094935
- 1990 - 19991567
- 1980 - 1989407
- 1975 - 197924
- Edizioni Minerva Medica24
- CIC Edizioni Internazionali15
- Oxford University Press10
- EUROPEAN JOURNAL OF NUCLEAR MEDIC...333
- DIGESTIVE AND LIVER DISEASE307
- THE JOURNAL OF NUCLEAR MEDICINE288
- THE JOURNAL OF UROLOGY236
- ANNALS OF ONCOLOGY229
- GASTROINTESTINAL ENDOSCOPY177
- JOURNAL OF CLINICAL ONCOLOGY170
- KNEE SURGERY, SPORTS TRAUMATOLOGY...162
- ANNUAL UPDATE IN INTENSIVE CARE A...2
- HANDBOOK OF EXPERIMENTAL PHARMACO...1
- METHODS IN MOLECULAR BIOLOGY1
- Middle Aged86
- Immunology and Allergy52
Accesso al fulltext
- no fulltext17566